Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shyam Patel

Orthopaedic Surgery of the Spine Providence, RI Medical Doctor

NPI 1326429408 CMS profile 1364233

2 Dudley St Ste 200, Providence, RI 02905

Open in the dashboard

General payments

$27,998

372 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shyam Patel of Providence, RI is reported in the CMS Open Payments database as having received $27,998 across 372 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,018 97
2024 General $4,538 101
2023 General $10,823 112
2022 General $1,112 15
2021 General $554 10
2020 General $845 8
2019 General $5,107 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shyam Patel
  • Orthopaedic Surgery of the Spine median
  • Middle half of Orthopaedic Surgery of the Spine
  • National median

In program year 2025, general payments to Shyam Patel were reported at $5,018. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.

Show as a table
Year Shyam Patel Orthopaedic Surgery of the Spine median Middle half National median
2019 $5,107 $2,106 $337–$18,608 $163
2020 $845 $1,213 $156–$15,082 $114
2021 $554 $1,834 $271–$15,617 $132
2022 $1,112 $2,015 $320–$17,036 $149
2023 $10,823 $1,925 $336–$14,599 $160
2024 $4,538 $2,110 $341–$12,483 $164
2025 $5,018 $2,061 $347–$14,651 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Globus Medical, Inc. $9,381 184 payments
  2. NuVasive, Inc. $5,688 63 payments
  3. Medtronic, Inc. $4,694 51 payments
  4. Southern Spine, LLC $3,113 2 payments
  5. Zimmer Biomet Holdings, Inc. $2,159 26 payments
  6. DePuy Synthes Sales Inc. $648 19 payments
  7. Smaio USA Corporation $376 2 payments
  8. Medical Device Business Services, Inc. $350 3 payments
  9. Cerapedics, Inc. $303 2 payments
  10. Stryker Corporation $281 7 payments
  11. Other $1,004 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,680 338 payments
  2. Travel and Lodging $10,824 30 payments
  3. Education $495 4 payments
Products named General payments · program years 2019–2025
  1. XLIF $4,590 36 payments
  2. MAZOR X SYSTEM $1,976 13 payments
  3. ExcelsiusGPS Robotic Navigation System $1,794 12 payments
  4. Affixus $1,663 17 payments
  5. STEALTHSTATION S8 PLATFORM $1,634 22 payments
  6. EXCELSIUS GPS $1,430 10 payments
  7. RELINE $1,030 14 payments
  8. ACP $912 23 payments
  9. SABLE $629 23 payments
  10. Modulus $465 7 payments
  11. Other $10,249 210 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,121

Median for Orthopedic Surgery: 203

Drug cost

$22,785

Median for Orthopedic Surgery: $1,433

Branded share of claims

1.3%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 15 $9,399
Gabapentin Generic 160 $1,614
Atorvastatin Calcium Generic 97 $1,447
Diclofenac Sodium Generic 58 $1,238
Levothyroxine Sodium Generic 50 $713
Tamsulosin Hcl Generic 33 $710
Mirtazapine Generic 18 $588
Divalproex Sodium Generic 16 $544
Omeprazole Generic 33 $412
Meloxicam Generic 140 $399

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$207,274

Medicare's payments for the services billed

Medicare patients

494

Average age 74

Services billed

1,141

284 women, 210 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 40%
Diabetes 29%
Osteoporosis 24%
Chronic kidney disease 22%
Depression 21%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

372 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record